DK1016711T3 - Fremgangsmåde til inaktivering af kappeklædte virus i et viruspræparat med adenovirus - Google Patents

Fremgangsmåde til inaktivering af kappeklædte virus i et viruspræparat med adenovirus

Info

Publication number
DK1016711T3
DK1016711T3 DK99403194T DK99403194T DK1016711T3 DK 1016711 T3 DK1016711 T3 DK 1016711T3 DK 99403194 T DK99403194 T DK 99403194T DK 99403194 T DK99403194 T DK 99403194T DK 1016711 T3 DK1016711 T3 DK 1016711T3
Authority
DK
Denmark
Prior art keywords
enveloped viruses
virus preparation
viral preparation
preparation
adenovirus virus
Prior art date
Application number
DK99403194T
Other languages
English (en)
Inventor
David Gaillac
Michel Koehl
Original Assignee
Transgene Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene Sa filed Critical Transgene Sa
Application granted granted Critical
Publication of DK1016711T3 publication Critical patent/DK1016711T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10361—Methods of inactivation or attenuation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10361—Methods of inactivation or attenuation
    • C12N2710/10363—Methods of inactivation or attenuation by chemical treatment

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicinal Preparation (AREA)
DK99403194T 1998-12-21 1999-12-17 Fremgangsmåde til inaktivering af kappeklædte virus i et viruspræparat med adenovirus DK1016711T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9816147A FR2787465A1 (fr) 1998-12-21 1998-12-21 Procede d'inactivation des virus enveloppes dans une preparation virale de virus non enveloppes
EP19990403194 EP1016711B1 (fr) 1998-12-21 1999-12-17 Procédé d'inactivation de virus enveloppés dans une préparation virale d'adénovirus

Publications (1)

Publication Number Publication Date
DK1016711T3 true DK1016711T3 (da) 2005-03-07

Family

ID=9534248

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99403194T DK1016711T3 (da) 1998-12-21 1999-12-17 Fremgangsmåde til inaktivering af kappeklædte virus i et viruspræparat med adenovirus

Country Status (11)

Country Link
US (2) US7026154B1 (da)
EP (1) EP1016711B1 (da)
JP (1) JP4459353B2 (da)
AT (1) ATE280823T1 (da)
AU (1) AU769121B2 (da)
CA (1) CA2292922C (da)
DE (1) DE69921435T2 (da)
DK (1) DK1016711T3 (da)
ES (1) ES2230820T3 (da)
FR (1) FR2787465A1 (da)
PT (1) PT1016711E (da)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1420065A4 (en) * 2001-08-02 2005-03-09 Anges Mg Inc PROCESS FOR PRODUCING INACTIVE VIRAL ENVELOPES
US7056723B2 (en) * 2001-12-20 2006-06-06 Bavarian Nordic A/S Method for the recovery and purification of poxviruses from infected cells
DE602004031681D1 (de) 2003-07-21 2011-04-14 Transgene Sa Multifunktionelle Cytokine
US20050197496A1 (en) * 2004-03-04 2005-09-08 Gtc Biotherapeutics, Inc. Methods of protein fractionation using high performance tangential flow filtration
AU2005229674B2 (en) * 2004-11-18 2010-11-04 Kedrion Melville Inc. Low concentration solvent/detergent process of immuneglobulin with pre-treatment
US20060130159A1 (en) * 2004-12-09 2006-06-15 Nick Masiello Method of purifying recombinant MSP 1-42 derived from Plasmodium falciparum
US7531632B2 (en) * 2006-02-16 2009-05-12 Gtc Biotherapeutics, Inc. Clarification of transgenic milk using depth filtration
PE20081723A1 (es) 2007-01-30 2008-12-14 Transgene Sa Vacuna contra el papilomavirus
MX2011007386A (es) 2009-01-20 2011-08-03 Transgene Sa Icam-1 soluble como un biomarcador para la prediccion de una respuesta terapeutica.
WO2010108908A1 (en) 2009-03-24 2010-09-30 Transgene Sa Biomarker for monitoring patients
JP5661738B2 (ja) 2009-04-17 2015-01-28 トランジェーヌ、ソシエテ、アノニムＴｒａｎｓｇｅｎｅ Ｓ．Ａ． 患者をモニターするためのバイオマーカー
CA2767458A1 (en) 2009-07-10 2011-01-13 Bruce Acres Biomarker for selecting patients and related methods
BR112012002628B1 (pt) 2009-08-07 2021-09-08 Transgene Sa Composição imunogênica, molécula de ácido nucleico, vetor, partícula viral infecciosa, micro-organismo transgênico, composição, usos da composição imunogênica e kit de partes
JP2013523175A (ja) 2010-04-14 2013-06-17 イーエムディー・ミリポア・コーポレーション 高力価、高純度のウイルスストックの作製方法及びその使用方法
US9029517B2 (en) 2010-07-30 2015-05-12 Emd Millipore Corporation Chromatography media and method
SG191781A1 (en) * 2010-12-30 2013-08-30 Lab Francais Du Fractionnement Glycols as pathogen inactivating agents
EP3587455A1 (en) 2012-10-23 2020-01-01 Emory University Gm-csf and il-4 conjugates, compositions, and methods related thereto
US10449517B2 (en) 2014-09-02 2019-10-22 Emd Millipore Corporation High surface area fiber media with nano-fibrillated surface features
US20170298091A1 (en) 2014-12-08 2017-10-19 Emd Millipore Corporation Mixed Bed Ion Exchange Adsorber
ES3011733T3 (en) 2015-02-13 2025-04-08 Transgene Immunotherapeutic vaccine and antibody combination therapy
WO2016131945A1 (en) 2015-02-20 2016-08-25 Transgene Sa Combination product with autophagy modulator
EP3452081A1 (en) 2016-05-04 2019-03-13 Transgene SA Combination therapy with cpg tlr9 ligand
EP3522920A2 (en) 2016-10-10 2019-08-14 Transgene SA Immunotherapeutic product and mdsc modulator combination therapy
JP7432506B2 (ja) 2017-10-30 2024-02-16 武田薬品工業株式会社 脂質エンベロープウイルスを不活化するための環境適合性の界面活性剤
US11690869B2 (en) * 2020-04-23 2023-07-04 Johnson & Johnson Consumer Inc. Methods of inhibiting enveloped viruses using low molecular weight hydrophobically modified polymers

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2007545A1 (en) * 1989-01-13 1990-07-13 Yahiro Uemura Production method for protein-containing composition
FR2705686B1 (fr) * 1993-05-28 1995-08-18 Transgene Sa Nouveaux adénovirus défectifs et lignées de complémentation correspondantes.
US6281010B1 (en) * 1995-06-05 2001-08-28 The Trustees Of The University Of Pennsylvania Adenovirus gene therapy vehicle and cell line
DE19623293C2 (de) * 1996-06-11 1998-10-22 Biotest Pharma Gmbh Nicht-immunogene Faktor VIII-enthaltende Zusammensetzung und ein Verfahren zu ihrer Herstellung
ATE353956T1 (de) * 1996-12-13 2007-03-15 Schering Corp Methoden zur virus-reinigung
DE19709186C2 (de) * 1997-03-06 1999-10-14 Medigene Ag Filtrationsverfahren zur Trennung von Viren

Also Published As

Publication number Publication date
AU769121B2 (en) 2004-01-15
US7026154B1 (en) 2006-04-11
JP2000201673A (ja) 2000-07-25
JP4459353B2 (ja) 2010-04-28
AU6535899A (en) 2000-06-22
ES2230820T3 (es) 2005-05-01
US7378265B2 (en) 2008-05-27
DE69921435D1 (de) 2004-12-02
EP1016711B1 (fr) 2004-10-27
FR2787465A1 (fr) 2000-06-23
ATE280823T1 (de) 2004-11-15
CA2292922A1 (fr) 2000-06-21
US20060166345A1 (en) 2006-07-27
DE69921435T2 (de) 2006-03-02
PT1016711E (pt) 2005-02-28
EP1016711A1 (fr) 2000-07-05
CA2292922C (fr) 2011-05-31

Similar Documents

Publication Publication Date Title
PT1016711E (pt) Processo de inactivacao de virus de envelope numa preparacao viral de adenovirus
ES8307500A1 (es) "metodo para inactivar los virus infecciosos contenidos en una composicion enzimatica hemocoagulante".
NO20073151L (no) Fremgangsmater og sammensetninger for a behandle hepatitt C virus
AR020054A1 (es) COMPOSICIoN QUE COMPRENDE UN ADENOVIRUS
WO2000034444A3 (en) Method and composition for preserving viruses
DK0530173T3 (da) Fremgangsmåde til inaktivering af prioner
NO951761L (no) Stabilt preparat for behandling av blodkoagulasjonssykdommer
GB2199328B (en) Use of a 5' untranslated leader sequence of an rna virus to enhance translation
DK0931830T3 (da) Cytopatiske vira til terapi og profylakse af neoplasi
DK0904351T3 (da) Dyreceller og fremgangsmåder til replikationen af influenzavirus
ATE219366T1 (de) Verwendung von 5-fluoro-2'-deoxy-3'-thiacytidin zur behandlung von hepatitis b
ATE335810T1 (de) Verfahren zur inaktivierung von lipidumhüllten viren
DK437988A (da) Fremgangsmaade til rensning af hepatitis a vironer
PL330407A1 (en) Substituted cyclopentane compounds useful as neuraminidaze inhibitors
DK57284A (da) Fremgangsmaade til inaktivering af et lipidvirus
FI911131A0 (fi) Menetelmä viherkaihia estävien 3-aryylikarbonyyli-1-aminoalkyyli-1H-indoliyhdisteiden valmistamiseksi
DK1149910T3 (da) Farmaceutisk præparat til behandling af papillomavirustumorer og -infektion
SE8505715D0 (sv) Indolderivat
DK0988302T3 (da) Benzonaphthyridiner
DK1235590T3 (da) Fremgangsmåde til behandling af en malignitet i en patient og et farmaceutisk præparat til anvendelse i samme
ATE346859T1 (de) Zusammensetzung zum zellspezifischen transfer von wirkstoffen
FI953756A7 (fi) Menetelmä lipidivaipattomien virusten inaktivoimiseksi
EP0909172A4 (en) METHODS AND COMPOSITIONS FOR TREATING URINARY INCONTINENCE WITH ENANTIOMERIC ENRICHED (R, s) -GLYCOPYRROLATE
EP0571771A3 (en) Method of inactivation of viruses in proteinic preparations
ATE150086T1 (de) Cdns-sequenz und detektion des hepatitis c-virus